Last checked at 
(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical, it announced on Wednesday, and to enter into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies, incorporating its 'Affimer' proteins to enhance the immune-modulatory effects.
The AIM-traded firm explained that mesenchymal stem cells (MSCs) are promising agents for the treatment of autoimmune and inflammatory diseases.
It said the joint venture would develop a new class of MSCs that would be primed to produce Affimer proteins, which were designed to enhance the immune-modulatory effect when administered to patients, by reducing inflammatory and autoimmune responses.
Avacta said it would develop Affimer proteins against several undisclosed targets, which would be transferred to the joint venture to be incorporated into MSCs.
Its research and development costs would be fully covered by the joint venture, which was being funded by Daewoong.
Avacta said it was retaining the rights to commercialise the Affimer proteins outside of the field of cell therapies.
Daewoong would provide the joint venture with access to its proprietary technology for generating allogeneic MSCs from a single donor to treat a large number of patients.
That technology would facilitate the development of cell therapies as 'off-the-shelf' products.
Avacta's shareholding in the joint venture would be 45%, and it would be operationally managed by Seng-ho Jeon, chief executive officer of Daewoong, with a board composed of representatives of both Avacta, being CEO Alastair Smith and vice-president of business development Matthew Vincent, as well as Daewoong.
"Cell and gene therapies are attracting intense clinical and commercial interest," said Avacta CEO Alastair Smith.
"We are very excited to establish this joint venture with Daewoong, one of the top pharmaceutical companies in Korea, to develop the Affimer platform in this important therapeutic area.
"Our vision is to combine our platforms to create the next generation of cell therapies, for which the potential is huge."
Dr Smith said that within the last six months, the firm had seen early stage stem cell companies acquired for significant sums, with Bayer acquiring control of Blue Rock for $600m, valuing that company at close to $1bn, and Vertex buying start-up Semma Therapeutics, which is developing stem cell therapies for type-1 diabetes, for $950m.
"This joint venture will have a unique opportunity to generate superior cell therapies for some of the most pressing needs in immune-mediated disease.
"We look forward to working closely with the Daewoong team to develop these new medicines, and get them to the patients who need them."
Dr Seng-ho Jeon, chief executive officer of Daewoong Pharmaceutical, added that the partnership reinforced the shared vision of the two firm in designing the next level of treatment paradigm, and would open up "a new horizon" in immunotherapeutic strategies.
"This innovative collaboration will deliver invaluable synergy and lead to new solutions to transform patients' lives."
At 1514 GMT, shares in Avacta Group were up 5.71% at 18.5p.
23 Apr 2024 14:26
UK earnings, trading statements calendar - next 7 days
| Wednesday 24 April | |
| 1Spatial PLC | Full Year Results |
| abrdn PLC | Trading Statement |
| Ecora Resources PLC | Trading Statement |
| Fresnillo PLC | Trading Statement |
| Lloyds Banking Group PLC | Q1 Results |
| Nichols PLC | Trading Statement |
| PensionBee Group PLC | First Quarter Results |
| PZ Cussons PLC | Trading Statement |
| Quilter PLC | Q1 Results |
| Reckitt Benckiser Group PLC | Trading Statement |
| Sanderson Design Group PLC | Full Year Results |
| Serica Energy PLC | Full Year Results |
| Star Energy Group PLC | Full Year Results |
| Tortilla Mexican Grill PLC | Full Year Results |
| Tracsis PLC | Half Year Results |
| Warpaint London PLC | Full Year Results |
| Thursday 25 April | |
| Aquila European Renewables PLC | Full Year Results |
| Argo Blockchain PLC | Full Year Results |
| AstraZeneca PLC | Q1 Results |
| Barclays PLC | Q1 Results |
| Checkit PLC | Full Year Results |
| Coca-Cola Europacific Partners PLC | Trading Statement |
| Destiny Pharma PLC | Full Year Results |
| Dillistone Group PLC | Full Year Results |
| Focusrite PLC | Half Year Results |
| Gem Diamonds Ltd | Trading Statement |
| Hikma Pharmaceuticals PLC | Trading Statement |
| Hummingbird Resources PLC | Trading Statement |
| Ibstock PLC | Trading Statement |
| Inchcape PLC | Trading Statement |
| J Sainsbury PLC | Full Year Results |
| London Stock Exchange Group PLC | Q1 Results |
| Persimmon PLC | Trading Statement |
| Pinewood Technologies Group PLC | Full Year Results |
| PPHE Hotel Group Ltd | Trading Statement |
| PureTech Health PLC | Full Year Results |
| Relx PLC | Trading Statement |
| Renewi PLC | Trading Statement |
| Schroders PLC | Q1 Results |
| Skillcast Group PLC | Full Year Results |
| Travis Perkins PLC | Trading Statement |
| Trifast PLC | Trading Statement |
| Unilever PLC | Q1 Results |
| WAG Payment Solutions PLC | Trading Statement |
| Weir Group PLC | Trading Statement |
| WH Smith PLC | Half Year Results |
| WPP PLC | Trading Statement |
| Zinc Media Group PLC | Full Year Results |
| Friday 26 April | |
| Facilities by ADF PLC | Full Year Results |
| Kingspan Group PLC | Trading Statement |
| NatWest Group PLC | Q1 Results |
| Pearson PLC | Trading Statement |
| Record PLC | Trading Statement |
| Smurfit Kappa Group PLC | Trading Statement |
| Taylor Maritime Investments Ltd | Trading Statement |
| Monday 29 April | |
| Beazley PLC | Trading Statement |
| Biome Technologies PLC | Full Year Results |
| Christie Group PLC | Full Year Results |
| Gresham Technologies PLC | Full Year Results |
| Jadestone Energy PLC | Full Year Results |
| Oxford BioMedica PLC | Full Year Results |
| SpaceandPeople PLC | Full Year Results |
| Tuesday 30 April | |
| Avacta Group PLC | Full Year Results |
| Card Factory PLC | Full Year Results |
| Capital & Regional PLC | Full Year Results |
| Coca-Cola HBC AG | Trading Statement |
| Elementis PLC | Trading Statement |
| essensys PLC | Half Year Results |
| Fadel Partners Inc | Full Year Results |
| Glencore PLC | Trading Statement |
| Hargreaves Lansdown PLC | Trading Statement |
| Howden Joinery PLC | Trading Statement |
| HSBC Holdings PLC | Q1 Results |
| Kelso Group PLC | Full Year Results |
| Northcoders Group PLC | Full Year Results |
| Phoenix Spree Deutschland Ltd | Full Year Results |
| RBG Holdings PLC | Full Year Results |
| Rotork PLC | Trading Statement |
| Safestore Holdings PLC | Half Year Results |
| Shield Therapeutics PLC | Full Year Results |
| St James's Place PLC | Trading Statement |
| Whitbread PLC | Full Year Results |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |